Carvedilol

Carvedilol

SCHEMBL22293

COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3

The experimentally established mechanism targets of Carvedilol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 known ✓ P07550 8/20 1.00
ADRB1 known ✓ P08588 1/20 1.00
ADRB3 known ✓ P13945 1/20 1.00
ADRA1D known ✓ P25100 1/20 1.00
ADRA1A known ✓ P35348 1/20 1.00
DRD2 P14416 3/20 1.00
MAPT P10636 2/20 1.00
TLR4 O00206 2/20 1.00
DNM1 Q05193 2/20 1.00
KDM4E B2RXH2 1/20 1.00
SLC22A2 O15244 1/20 1.00
SLC22A1 O15245 1/20 1.00
MLNR O43193 1/20 1.00
NR1I2 O75469 1/20 1.00
KCNK2 O95069 1/20 1.00
ABCB11 O95342 1/20 1.00
APP P05067 1/20 1.00
ABCB1 P08183 1/20 1.00
HTR1A P08908 1/20 1.00
ADRA2A P08913 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16549969 1.00 ADRB2 (1.00) ADRB2DRD2MAPTTLR4DNM1
(R)-Carvedilol SCHEMBL29382761 1.00 ADRB2 (1.00) ADRB2DRD2MAPTTLR4DNM1
Carvedilol SCHEMBL29370188 1.00 ADRB2 (1.00) ADRB2DRD2MAPTTLR4DNM1
Carvedilol SCHEMBL29687280 1.00 ADRB2 (1.00) ADRB2DRD2MAPTTLR4DNM1
Carvedilol SCHEMBL29744884 1.00 ADRB2 (1.00) ADRB2DRD2MAPTTLR4DNM1
Carvedilol SCHEMBL1560204 1.00 ADRB2 (1.00) ADRB2DRD2MAPTTLR4DNM1
(R)-Carvedilol SCHEMBL29744872 1.00 ADRB2 (1.00) ADRB2DRD2MAPTTLR4DNM1
(R)-Carvedilol SCHEMBL232110 1.00 ADRB2 (1.00) ADRB2DRD2MAPTTLR4DNM1
Carvedilol SCHEMBL10082334 1.00 ADRB2 (1.00) ADRB2DRD2MAPTTLR4DNM1
Carvedilol SCHEMBL1172788 1.00 ADRB2 (1.00) ADRB2DRD2MAPTTLR4DNM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 33866 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3607938-B1 PHARMACEUTICAL COMPOSITION SOVIC BRKICIC LJILJANA (HR) 2026-05-27 EP claimed
CN-116824393-B Lake chlorophyll inversion method based on migration learning and semi-supervised regression model 吉林大学 2026-05-15 CN claimed
WO-2026100654-A1 NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD 株式会社インファーマシア 2026-05-15 WO claimed
US-20260115166-A1 COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF PHOTORECEPTOR ROD DEGENERATIONS AND GENERATION OF PHOTORECEPTORS PURDUE RESEARCH FOUNDATION (US) 2026-04-30 US claimed
EP-4727545-A2 COMBINATION TREATMENTS FOR DEPRESSION AND OTHER DISORDERS Neurawell Therapeutics (US) 2026-04-22 EP claimed
EP-4722714-A1 SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) Korea Institute of Science and Technology (KR) 2026-04-08 EP claimed
EP-3746081-B1 PDE1 INHIBITORS FOR USE TO TREAT CARDIAC FAILURE AND CARDIOTOXICITY INTRA CELLULAR THERAPIES INC (US) 2026-04-01 EP claimed
US-20260076953-A1 METHODS OF DIAGNOSING AND TREATING ADHD IN BIOMARKER POSITIVE SUBJECTS THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) 2026-03-19 US claimed
US-20260069555-A1 Compositions and Methods for Modulating the Effect of Beta-Blocker Activity in a Subject UNIV DUKE (US) 2026-03-12 US claimed
US-12550885-B2 Red blood cell storage solutions, solution additives, and methods for improving the storage of red blood cells UNIVERSITY OF CINCINNATI (US) 2026-02-17 US claimed
US-5453436-A Treatment of athereosclerosis using, carbazolyl-(4)-oxypropanolamine compounds BOEHRINGER MANNHEIM PHARMACEUTICAL CORPORATION (US) 1995-09-26 US claimed
EP-0648118-A1 METHODS AND PRODUCTS FOR TREATING PRESBYOPIA TELOR OPHTHALMIC PHARMACEUTICALS, INC. (US) 1995-04-19 EP claimed
US-5399581-A Method and compositions for treatment of sexual impotence LARAGH JOHN H (US) 1995-03-21 US claimed
EP-0625903-A1 TOPICAL ANTIGLAUCOMA COMPOSITIONS COMPRISING CARBONIC ANHYDRASE INHIBITORS AND BETA-BLOCKERS ALCON LABORATORIES, INC. (US) 1994-11-30 EP claimed
WO-1994020097-A1 USE OF, AND METHOD OF TREATMENT USING, CARBAZOLYL-(4)-OXYPROPANOLAMINE COMPOUNDS FOR INHIBITION OF SMOOTH MUSCLE CELL PROLIFERATION BOEHRINGER MANNHEIM PHARMACEUTICALS CORPORATION-SMITHKLINE BEECHAM CORPORATION LIMITED PARTNERSHIP NO. 1 (US) 1994-09-15 WO claimed
WO-1994020096-A1 METHOD OF EMPLOYING CARBAZOLYL-(4)-OXYPROPANOLAMINE COMPOUNDS FOR INHIBITION OF SMOOTH MUSCLE CELL PROLIFERATION BOEHRINGER MANNHEIM PHARMACEUTICALS CORPORATION - SMITHKLINE BECKMAN CORPORATION LIMITED (US) 1994-09-15 WO claimed
US-5308862-A Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation BOEHRINGER MANNHEIM PHARMACEUTICALS CORPORATION - SMITHKLINE BEECHAM CORP., LTD. PARTNERSHIP NO. 1 (US) 1994-05-03 US claimed
WO-1994001096-A1 METHODS AND PRODUCTS FOR TREATING PRESBYOPIA TELOR OPHTHALMIC PHARMACEUTICALS, INC. (US) 1994-01-20 WO claimed
WO-1993016701-A2 TOPICAL ANTIGLAUCOMA COMPOSITIONS COMPRISING CARBONIC ANHYDRASE INHIBITORS AND BETA-BLOCKERS ALCON LABORATORIES, INC. (US) 1993-09-02 WO claimed
WO-1992011851-A1 METHOD AND COMPOSITIONS FOR TREATMENT OF SEXUAL IMPOTENCE LARAGH JOHN H (US) 1992-07-23 WO claimed